morning welcome scientific first quarter conference call operator instruction operator instruction would like introduce moderator call vice president investor relation begin call vice president investor relation good morning thank join call today chairman president chief executive officer senior vice president chief financial officer please note call webcast live archive investor section website thermofisher head webcast presentation copy press release first quarter earn available investor section website head financial result begin briefly cover safe harbor statement various remark make company future expectation plan prospect constitute forward look statement purpose safe harbor provision private security litigation reform actual result differ materially indicate forward look statement result various important factor include discuss company recent annual report form file available investor section website head file like update forward look statement point future specifically disclaim obligation even estimate change therefore rely forward look statement represent view date subsequent today also call refer certain financial measure prepare accordance generally accept account principle reconciliation financial measure directly comparable measure available press release first quarter earn also investor section website head financial information turn call chairman president chief executive officer thank good morning everyone thank join call press release strong start year deliver another quarter outstanding financial performance excellent growth bottom line know play significant role enable society response pandemic include rapidly expand role support vaccine production base business meaningfully accelerate growth across business first quarter strong execution growth strategy include launch number innovative product capitalize leadership high growth emerge market strengthen unique customer value proposition already start benefit accelerate investment initiate continue execute capital deployment strategy complete acquisition viral vector business biotech rapid point care molecular diagnostics company also return capital shareholder stock buyback dividend sure shortly quarter close announce agreement acquire lead provider clinical research service serve pharma biotech customer fastest grow market another great quarter deliver stakeholder near term invest organically inorganically great future cover topic depth remark first recap financials revenue grow year year billion adjust operate income first quarter increase billion adjust operate margin expand percentage point finally deliver another quarter strong adjust performance achieve increase share turn market condition robust drive three factor strong fundamental life science ramp economic activity globally role industry play pandemic response unique competitive position allow deliver another fantastic quarter start pharma biotech outstanding performance growth approximately drive strong underlie market dynamic benefit unique customer value proposition lead role support customer across wide range excite therapeutic area include significant role support vaccine therapy excellent growth across business serve customer include bioproduction pharma service bioscience chromatography mass spectrometry research safety market channel clearly benefit trust partner status earn many year customer academic government strong performance grow drive robust customer activity globally strong growth across number business support customer base particularly bioscience chromatography mass spectrometry electron microscopy turn industrial apply grow double digit first quarter continue execute high level capture opportunity customer increase activity level quarter good strong growth across instrument business finally diagnostics healthcare another outstanding quarter deliver approximately growth demand test solution strong base business demand still pandemic level encourage immunodiagnostics business return strong growth quarter summarize performance capitalize improve condition market continue gain market share give update role support pandemic response quarter play meaningful role fight globally generate billion response revenue demand test solution strong role development production vaccine therapy continue ramp even faster expect come year expect role support vaccine therapy represent billion revenue base order speed capacity expansion come online expect deliver billion vaccine therapy revenue also continue leverage expertise bring solution fight example quarter launch scientific monitor system help facility hospital school business identify presence pathogen include virus cause people return public space complement safety protocol also acquire biotech simple rapid test test include doctor office pharmacy support number back life application customer interest high business system scale manufacture rapid diagnostic cartridge expect generate million year capability excite potential molecular diagnostic technology post pandemic point would like make lead role play pandemic response outstanding financial performance able significantly accelerate investment program last year commercial enablement capability capacity expansion accelerate investment really position even brighter future glimpse early momentum build investment turn great progress make growth strategy base three pillar launch high impact innovative product leverage scale high growth emerge market deliver unique value proposition customer share example demonstrate strategy continue build success create value customer start innovation quarter launch number product across business strengthen lead position enable customer break achieve goal highlight chromatography mass spectrometry launch scientific mass spectrometer extend impact industry lead franchise bring high resolution analysis range application include toxicology metabolomics material structural analysis launch scientific spectrum ultra generation scan transmission electron microscope material science application provide insight atomic scale resolution accelerate research improve manufacture productivity bioscience business launch purification system high throughput sample preparation turn second pillar growth strategy leverage scale create outstanding experience customer high growth emerge market excellent growth particularly customer activity return pandemic level grow continue strengthen capability serve market example quarter start ship product single facility localize bioproduction manufacture biotech customer investment bioproduction capability single capacity pharma biotech customer globally strong momentum high growth emerge market continue strengthen position turn third pillar growth strategy customer value proposition continue increase capability capacity even better partner customer help achieve goal update progress serve pharma biotech customer upcoming acquisition leader clinical trial management service great complement role play support research development clinical trial production combine capability along complementary reputation excellent quality service enhance value proposition pharma biotech customer importantly customer able efficiently access service enablers success interact number customer since announcement excite capability bring scientific highly complementary service portfolio able advance strategic partnership customer work bring scientific idea improve medicine also provide terrific career opportunity colleague create significant shareholder value organic investment also build capability capacity pharma biotech customer lens highlight support scale vaccine high demand globally today also many disease forward know important supplier area continue invest scale capacity include bioscience business build additional capacity central material different region world also expand bioproduction purification resin capacity manufacture process finally ensure expand regionally available sterile fill finish capacity produce final drug product always business system help drive success quarter enable find solution better serve customer work efficiently effectively create even greater value stakeholder give quick summary capital deployment activity year active start close billion acquisition quarter mention enter agreement acquire billion plus assumption approximately billion debt also return significant capital shareholder quarter repurchase billion share increase dividend great start year capital deployment front pipeline remain active turn brief update progress initiative mission enable customer make world healthier cleaner safer never relevant addition want make positive impact community live work proud past year significantly increase social impact first quarter commit impact investment million support financial institution serve black minority community business like project foundation science launch last year recent investment mean help create opportunity turn guidance drive strong start year confidence full year outlook raise revenue earn guidance full year assumption behind guidance cover highlight raise revenue guidance million billion represent report growth term adjust raise guidance represent growth turn call summarize takeaway deliver another excellent quarter financial performance bottom line market strong commit execute continue execute prove growth strategy even stronger partner customer effectively deploy capital create significant value customer shareholder excite plan acquire much look forward welcome colleague expect later year finally like thank colleague dedication company customer deliver another fantastic quarter turn call senior vice president chief financial good morning everyone begin high level summary performance mention another exceptional quarter grow revenue include organic growth deliver billion response revenue accelerate growth base business great start year line also excellent start year adjust grow higher expectation time last earn call drive great operational execution time expense within year higher tailwind overall exceptional financial result continue momentum provide additional detail performance quarter last year line report revenue grow year year component report revenue increase include organic growth tailwind foreign exchange acquisition reminder three extra sell represent tailwind approximately look ahead four fewer turn performance geography quarter region deliver strong growth north pacific grow approximately grow rest world grow turn operational performance adjust operate income increase adjust operate margin percentage point higher last year quarter business system enable drive exceptional volume leverage strong productivity also favorable business tailwind partially offset strategic investment across business support near long term growth move detail total company adjust gross margin quarter come basis point prior year increase gross margin similar driver adjust operate margin adjust quarter revenue decrease basis point versus reflect strong volume leverage total expense million represent growth reflect increase investment high impact innovation fuel future growth look result line quarter interest expense million million higher last year adjust income expense income quarter approximately million million lower mainly change nonoperating line expectation adjust rate quarter basis point versus last year substantial increase profit average dilute share million million lower year year drive share repurchase option dilution turn cash flow balance sheet cash flow another strong highlight quarter business system enable deliver significant cash flow strong line performance cash flow continue operation billion free cash flow billion capacity capability investment proceed quarter capital expenditure million quarter return billion capital shareholder buyback billion million march quarter also increase dividend deploy billion acquisition include biotech acquisition base viral vector business shortly quarter also announce agreement acquire early quarter complete redemption billion senior note approximately billion cash billion total debt leverage ratio quarter time gross debt adjust time debt basis conclude comment total company performance adjust basis point last year continue generate exceptional return provide color performance four business segment similar last quarter start frame think impact response segment result revenue standpoint case last quarter majority response revenue recognize life science solution remainder recognize specialty diagnostics laboratory product service segment margin standpoint impact differ across segment base scale response revenue different level profitability revenue addition quarter continue make strategic investment across business include investment commercial production capacity size investment necessarily align response revenue segment skew report segment margin move part segment margin standpoint reflect active management company successfully navigate current environment position company even brighter future move segment detail start life science solution report revenue segment increase organic growth quarter exceptionally strong growth genetic science bioscience bioproduction business adjust operate income life science solution increase adjust operate margin percentage point year year quarter drive strong volume pull positive business continue make strategic investment across business segment also tailwind margin segment analytical instrument segment report revenue increase organic growth quarter strong growth chromatography mass spectrometry material structural analysis business good chemical analysis return growth adjust operate income analytical instrument increase adjust operate margin basis point year year quarter drive strong volume leverage productivity offset strategic investment turn specialty diagnostics segment report revenue increase organic revenue growth response enable deliver strong growth microbiology healthcare market channel clinical diagnostics business addition good immunodiagnostics business return growth adjust operate income increase quarter adjust operate margin basis point prior year drive strong volume leverage partially offset unfavorable business strategic investment lastly laboratory product service segment report revenue increase organic growth quarter strong growth business segment adjust operate income segment increase adjust operate margin basis point higher prior year quarter deliver strong volume pull productivity partially offset strategic investment turn update guidance consistent approach take initial guidance provide point outlook rather range think helpful approach give multitude different potential customer demand outcome year mention raise revenue adjust guidance walk detail begin revenue raise revenue guidance million billion represent report growth include organic growth increase drive three factor million increase improve organic growth outlook base business strong start year enable increase base business organic growth full year million increase come higher impact acquisition reflect acquisition biotech include initial guidance good start year viral vector business final element increase million higher tailwind turn adjust earn share increase annual adjust guidance would result growth increase reflect improve operational outlook year capital deployment break increase impact capital deployment versus initial guide include additional interest placeholder prefinancing acquisition offset benefit million stock buyback undertake march benefit acquisition great start able increase outlook full year provide additional assumption behind update guidance assume deliver billion response revenue million higher initial guidance reflect acquisition biotech within billion assume vaccine therapy relate revenue approximately billion year million higher initial guidance assumption reflect strong customer demand progress capacity expansion project still remain large range outcome test demand remain position support customer regard assume year year tailwind million revenue adjust assume complete acquisition contribute million report revenue growth guidance include operational benefit acquisition clarity actual close date provide estimate likely impact mention earlier include million adjust impact higher interest guide placeholder prefinancing transaction expect interest expense approximately million continue expect adjust income rate change prior guidance assume capital expenditure approximately billion billion million higher initial guidance year continue identify opportunity support future customer demand capacity capability expansion pharma service bioproduction bioscience laboratory product business free cash flow expect approximately billion change prior guidance guidance include billion capital deployment billion share buyback complete billion complete million capital return shareholder dividend estimate full year average dilute share count million share finally want touch quarterly phase year give reminder factor outline give initial guidance first mention earlier three extra sell four fewer response revenue guidance significantly weight first half year comparison significantly easier begin year strong growth first half year give revenue phase adjust weight first half year summary start year excellent great position achieve goal year turn call back vice president investor relation thank operator ready take question